A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab inCombination with Platinum-based Chemotherapy for the First-line Treatment of Patients with MetastaticNon-squamous Non-small Cell Lung Cancer Whose...
Purpose
The purpose of ARTEMIDE-Lung03 is to assess the efficacy and safety of rilvegostomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1st Line treatment in participants with non-squamous metastatic Non-Small Cell Lung Cancer & whose tumors express PD-L1 (TC ≥ 1%).
For more information please visit https://clinicaltrials.gov/study/NCT06627647
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671 .
Share
